Flat 20% off on Medicines Genuine branded products Quality Assured Secure payment Delivery across 25000+ pincodes Assured Savings Multiple payment options

Fill the quantity to get latest price!


Composition : Erlotinib Hydrochloride

Manufacturer : Cipla

Indication : Lung cancer

Packaging : Bottle

Dosage Form : Tablet



Overview of Erlocip  

Erlocip is a formulation of Erlotinib, an EGFR tyrosine kinase inhibitor. This prescription medication is used in the treatment of patients suffering from metastatic non-small cell lung cancer (NSCLC). It is prescribed specifically to the patients whose tumors have epidermal growth factor receptor exon 19 deletions or evidence of exon 21 substitution mutations after progression due to at least one prior treatment with chemotherapy drugs. Erlocip is available in the form of tablets with a fixed strength of 150 mg for oral administration only. Several tests may be recommended by the medical team during Erlocip therapy to keep a check on the liver and kidney function. 

The active compound present in Erlocip tablets is Erlotinib. Its inactive ingredients are sodium starch glycolate, titanium dioxide, sodium lauryl sulfate, lactose monohydrate, hydroxypropyl cellulose, microcrystalline cellulose, magnesium stearate, and hypromellose. Erlocip tablet is an inhibitor of the epidermal growth factor receptor tyrosine kinase that is also indicated for use as a combination therapy with first-line treatment in patients diagnosed with pancreatic cancer. S mechanism of action has not been fully established. 


All medicines interact differently from person to person. However, some interactions associated with the use of Erlocip tablets, that are common to all, are mentioned below: 

Medicine interactions: Erlocip (Erlotinib) tablets can interact with certain medications including Atazanavir, Ciprofloxacin, Carbamazepine, Clarithromycin, Fluvoxamine, Pantoprazole, and Lansoprazole. It becomes important to check the risks of such interactions with the medical team prior to the administration of your first Erlocip dose. Ask your doctor about the dose adjustments or discontinuation / substitute of any regimen you administer already. 

Disease interactions: Erlocip (Erlotinib) tablets can interact with certain conditions associated with diseases including gastrointestinal disorder, eye disorder, renal impairment, and hepatic impairment. It becomes important to check the risks of such interactions with the medical team prior to the administration of your first Erlocip dose. Ask your doctor about the dose adjustments of Erlocip tablets, if required. 

Food interactions: Grapefruit/grapefruit products and St. John’s Wort can cause severe interactions with Erlocip (Erlotinib) tablets by increasing and decreasing the serum level of Erlotinib respectively. It becomes important to avoid such food items. Also, it is advisable to administer Erlocip (Erlotinib) tablets on an empty stomach (at least an hour before or two hours after a meal) since food can significantly increase the bioavailability of Erlotinib.

Q1. What is Erlocip (Erlotinib)?

Ans. Erlocip (Erlotinib) tablet is an anti-cancer medication used for the treatment of non-small cell lung cancer and pancreatic cancer that has spread to other parts of the body. This medication interferes with the growth of cancer cells and slows their spread in the body.

Q2. What are the side effects?

Ans. Some common side effects are – vomiting, blurred vision, cough, fever and chills, loss of appetite, dizziness, back pain, chest pain, hair loss, anxiety, itching, rash, indigestion, decreased weight, etc.

Q3. How to take this medicine?

Ans. It is important to take the Erlocip tablet as prescribed by your doctor. Swallow the whole tablet with a glass of water and take it regularly at the same time every day. Do not take this medicine in the wrong way as it may lead to some severe side effects.

Q4. Can I take this medicine during pregnancy?

Ans. Do not use Erlocip tablet if you are pregnant or planning to become pregnant. This medication can cause harm to the unborn baby.

Q5. What should I avoid while having treatment with this medicine?

Ans. Avoid contact with people who have infections and avoid any hazardous activity. Follow your doctor’s instructions and restrictions about any food and other activities.

Q6. How does Erlocip (Erlotinib) work?

Ans. This medication is designed to barricade tumor cell growth by targeting a protein EGFR (epidermal growth factor) that is existing on the surface of some cancer cells and some normal cells.  Erlocip tablet stops an enzyme within the cell (tyrosine kinase) that is associated with EGFR. 

Q7. What happens if I miss a dose? 

Ans. If you miss a scheduled dose of Erlocip tablet, contact your doctor immediately. Do not stop or change your dosing schedule without taking suggestions from your doctor. 

Q8. What are the storage conditions?

Ans. Store this medicine at room temperature. Keep it away from direct heat and light. Please consult your pharmacist or doctor for more details regarding the Erlocip (Erlotinib).

Q9. Can I drive after taking this medicine?

Ans. Erlocip tablets may cause dizziness in some patients. Do not drive if you experience any symptoms of dizziness because it may affect your ability to drive.

Q10. What are the warnings and precautions?

Ans. Before starting treatment with Erlocip tablet, please inform your doctor about your previous medical history.

  • Do not use this medicine if you are allergic to Erlotinib.
  • Regular monitoring of liver, kidney, and lung function is required during treatment with this medication.
  • Erlocip medication may reduce platelets counts 
  • Do not crush or break the tablet. 
Reviews (0)


There are no reviews yet.

Be the first to review “Erlocip”

Your email address will not be published. Required fields are marked *